VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –